Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Nov 16, 2025
Reporting period
Not applicable
Filed with the SEC
Nov 17, 2025
CEOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001628280-25-052715
Filed / recorded
Nov 17, 2025, 10:48 PM UTC
Added to OQRO
Oct 8, 2026, 12:20 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Humacyte, Inc.
Issuer CIK
1818382
Ticker
HUMA
Reporting person
Laura E Niklason
Relationship
Director, Officer
Officer title
President, CEO and Director
Security
Stock Options (right to buy)
Table
Derivative (Table II)
Transaction date
Nov 16, 2025
Transaction code
A
Shares / units
311,100
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
311,100
Ownership form
Direct
Amendment
No
Footnotes from the filing
The first 1/3 of the option becomes exercisable on February 14, 2026, after which 1/3 of the option will become exercisable on November 16, 2026, and the remaining 1/3 of the option will become exercisable on November 16, 2027.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.